(E)-7-(naphthalen-1-yl)-5-oxohept-6-enoic acid | 1254320-35-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-7-(naphthalen-1-yl)-5-oxohept-6-enoic acid
• 英文别名: (E)-7-naphthalen-1-yl-5-oxohept-6-enoic acid
• CAS: 1254320-35-8
• 化学式: C₁₇H₁₆O₃
• 分子量: 268.312
• InChiKey: YPZFDNHGPMQOIR-VAWYXSNFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-氯甲酰基丁酸甲酯 在 sodium hexamethyldisilazane 、 sodium iodide 、 potassium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醚 、 乙腈 为溶剂， 反应 43.25h， 生成 (E)-7-(naphthalen-1-yl)-5-oxohept-6-enoic acid
  参考文献：
  名称：

  5-Oxo-ETE Receptor Antagonists

  摘要：

  5-Oxo-ETE is the most powerful eosinophil chemoattractant among lipid mediators. Eosinophil infiltration into the lungs of asthmatics may be responsible for the late phase of inflammatory asthma. We have designed and synthesized a 5-oxo-ETE receptor antagonist, the purpose of which is to prevent eosinophil migration to the lung during an asthma attack and thereby reduce asthma symptoms.

  DOI：

  10.1021/jm400480j

文献信息

• [EN] 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS<br/>[FR] COMPOSÉS ANTAGONISTES DES RÉCEPTEURS 5-OXO-ETE
  申请人：UNIV MCGILL

  公开号：WO2010127452A1

  公开（公告）日：2010-11-11

  The present invention relates to novel pharmaceutically-useful compounds which are antagonists of the 5-oxo-ETE receptors, such as the OXE receptor. These compounds have use as therapeutic and/or prophylactic agents for diseases characterized by tissue eosinophilia, such as inflammatory conditions including respiratory diseases. The invention also relates to pharmaceutical compositions, to the use of such compounds and compositions as medicaments, and to therapeutic methods.

  本发明涉及一种新型的药用化合物，它们是5-oxo-ETE受体的拮抗剂，如OXE受体。这些化合物可用作治疗和/或预防组织嗜麻细胞增多等疾病的药物，如包括呼吸道疾病在内的炎症性疾病。该发明还涉及制药组合物，以及将这些化合物和组合物用作药物、以及治疗方法。
• 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS
  申请人：Powell William S.

  公开号：US20120122942A1

  公开（公告）日：2012-05-17

  The present invention relates to novel pharmaceutically-useful compounds which are antagonists of the 5-oxo-ETE receptors, such as the OXE receptor. These compounds have use as therapeutic and/or prophylactic agents for diseases characterized by tissue eosinophilia, such as inflammatory conditions including respiratory diseases. The invention also relates to pharmaceutical compositions, to the use of such compounds and compositions as medicaments, and to therapeutic methods.

  本发明涉及一种新型药用化合物，其为5-oxo-ETE受体（如OXE受体）的拮抗剂。这些化合物可用作治疗和/或预防组织嗜酸性细胞增多症的疾病的治疗剂和/或预防剂，例如包括呼吸系统疾病在内的炎症性疾病。本发明还涉及制药组合物，使用这种化合物和组合物作为药物以及治疗方法。
• US8809382B2
  申请人：——

  公开号：US8809382B2

  公开（公告）日：2014-08-19
• US9464048B2
  申请人：——

  公开号：US9464048B2

  公开（公告）日：2016-10-11
• 5-Oxo-ETE Receptor Antagonists
  作者：Vivek Gore、Pranav Patel、Chih-Tsung Chang、Sashikala Sivendran、Namin Kang、Yannick P. Ouedraogo、Sylvie Gravel、William S. Powell、Joshua Rokach

  DOI：10.1021/jm400480j

  日期：2013.5.9

  5-Oxo-ETE is the most powerful eosinophil chemoattractant among lipid mediators. Eosinophil infiltration into the lungs of asthmatics may be responsible for the late phase of inflammatory asthma. We have designed and synthesized a 5-oxo-ETE receptor antagonist, the purpose of which is to prevent eosinophil migration to the lung during an asthma attack and thereby reduce asthma symptoms.